
This article presents a near-miss event in which a patient with metastatic castration-resistant prostate cancer underwent emergency orthopedic surgery 21 days after Radium-223 administration. A safe outcome in this case depended on two coincidences: an incidental discovery of treatment history by a nurse and sufficient elapsed time for decay and clearance. Without the former, surgery would have proceeded without radiological assessment or appropriate precautions; without the latter, standard radiation safety precautions alone would have been insufficient to manage the hazard even with full radiological awareness. Through root cause analysis, we identified an information gap and an unrecognized dependence on favorable boundary conditions as the primary latent vulnerabilities. To quantify the unmanaged hazard, a deterministic hazard estimation demonstrated that surface contamination could have reached 386-fold above the US regulatory limit if the emergency had occurred 1 hour after administration. However, it fell sharply to approximately the regulatory limit at 24 hours due to physical decay and biological clearance. Crucially, even with minimal hemorrhage (30 mL), the contamination 1 hour after administration would still exceed the US statutory threshold 5.8-fold. These findings support a conceptual reframing: time functions as an intrinsic safety measure in radioisotope therapy by reducing the hazard itself through physical decay and biological clearance, independent of human compliance. Because compliance-driven administrative controls remain vulnerable during acute emergencies, institutions must explicitly operationalize time as an autonomous safety measure. To achieve this, we propose a three-tiered governance framework established at therapy initiation—that explicitly recognizes time as an intrinsic safety measure—assigning clear responsibilities to the prescribing physician as the primary clinical lead, the Radiation Safety Committee for operational protocols, and hospital executive management for infrastructure deployment.
Purpose Many people affected by cancer benefit from self-management, but this requires support from cancer care clinicians. Currently, there is a lack of consensus about the minimum competencies required of clinicians to facilitate effective self-management support (SMS). Methods A two-round online modified Delphi study involving cancer care clinicians was conducted to reach consensus on which performance criteria from a comprehensive SMS framework for cancer nurses should be considered minimum competencies that cancer care clinicians should possess. The perspectives of people affected by cancer regarding SMS needs were collected via online interviews and further shaped the statements. The project team finalized a list of minimum competencies for care-providers (care-provider version) and a reader-adjusted version for people affected by cancer (patient version). Results 27 clinicians and 14 people affected by cancer participated. Eighteen performance criteria from the original framework reached consensus for inclusion as minimum competencies, with participant feedback informing refinements to both the care-provider and patient versions. The performance criteria included statements from all six domains of the original framework: person-centered and motivational communication, whole-person assessment of SMS needs and capacity, health promotion theories and interventions, coaching for behavior change tailored to the individual, monitoring and evaluating change in self-management behaviors and health outcomes, and quality improvement for integration of SMS in cancer care. Conclusion The minimum competencies for SMS can be used to inform care provider education, skills assessment, and encourage patient activation for improved support, to optimize patient outcomes and health care utilization. International organizations, such as the Multinational Association for Supportive Care in Cancer, represent an ideal forum for the dissemination and strengthening of these competencies, and for local implementation.
Purpose Authorship of phase III oncology trials reflects broader patterns of scientific leadership, including access to resources, research infrastructure, and global participation. However, how these factors intersect with gender over time remains incompletely characterized. We evaluated trends in authorship across phase III solid-tumor trials presented at the ASCO Annual Meeting from 2015 to 2025. Methods We conducted a repeated cross-sectional study of phase III solid-tumor abstracts presented at ASCO (2015-2025). Author gender was assigned using a multistep approach based on publicly available data. Outcomes included authorship by role (first v senior), tumor track, funding source, trial-origin geographic region, and trial-origin World Bank income group. Multivariable logistic regression identified factors associated with female authorship. Results Among 1,517 abstracts (3,034 authorships), 27.9% of authors were women. Female authorship increased from 24.9% in 2015-2020 to 30.0% in 2021-2025 ( P = .002). Women were more likely to be first than senior authors (54.7% v 45.3%, P = .002) and were less likely to hold senior authorship overall (adjusted odds ratio [OR], 0.76, 95% CI 0.65-0.90; P = .001). Temporal gains were driven by increased female senior authorship (OR, 1.55 [95% CI, 1.20 to 1.99]; P = .001). Female authorship was lower in several tumor types and in East Asia and Pacific versus North America (OR, 0.65 [95% CI, 0.48 to 0.87]; P = .003). Funding and income group were not associated with female authorship. Conclusion Women remain underrepresented in phase III oncology trial authorship, particularly in senior roles and across certain tumor types and regions, suggesting persistent gaps in authorship representation that may reflect broader structural barriers.
Purpose Breast cancer survivorship care requires systematic approaches to identify and address patient-identified needs after completion of treatment. Methods Breast cancer survivors completing curative-intent treatment were referred to a risk-adapted survivorship program incorporating a structured previsit patient-reported concerns assessment. Descriptive analyses characterized the prevalence and longitudinal consistency of survivor-reported concerns. Aggregated concerns data supported real-time clinical decision making during survivorship visits and informed program-level planning, including alignment of consultative services and survivorship education embedded within routine oncology care. Results Two thousand five hundred fifty-eight breast cancer survivors completed the previsit patient-reported concerns assessment during survivorship visits from 2019 through 2025. Survivors reported a consistent set of physical, psychosocial, and lifestyle-related concerns across the study period. These survivor-identified concerns informed referral to established consultative services and guided development of survivorship education aligned with survivor-identified needs. Concern patterns were reviewed longitudinally to support alignment of survivorship services and education with evolving survivor priorities. Conclusion Integration of structured patient-reported concerns into routine survivorship care is feasible and supports responsive, patient-centered care delivery. This pragmatic approach may inform scalable, real-world implementation of survivorship program models without disrupting existing clinical workflows.